IRONWOOD PHARMACEUTICALS INC (IRWD): Nasdaq/NYSE listing notice — Ironwood receives Nasdaq notice for late 10-K filing; 60 days to submit compliance plan

IRONWOOD PHARMACEUTICALS INC

Nasdaq notified Ironwood on March 21, 2025 of non-compliance due to delayed 2024 Form 10-K filing.
Company has until May 20, 2025 to submit a plan; if accepted, extension to September 1, 2025.
No immediate effect on listing; Ironwood expects to file 2024 Form 10-K as soon as practicable.
Press release issued March 27, 2025; standard Nasdaq procedure for late filings.

item 3.01 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.98

IRONWOOD PHARMACEUTICALS INC received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: late filing
Rules: 5250(c)(1)

Exact text from the filing

daq Stock Market LLC (“Nasdaq”) indicating that, as a result of the Company’s delay in filing its Annual Report on Form 10-K for the year ended December 31, 2024 (the “2024 Form 10-K”) with the Securities and Exchange Commission (the “SEC”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which requires Nasdaq-listed companies to timely file all required periodic financial reports with the SEC. The Notice states that the Company has 60 calendar days from the date of the Notice, or until May 20, 2025, to submit a plan to regain compliance with the Rule. If Nas

View on SEC.gov

50 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

IRONWOOD PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001104659-25-028766

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.